certus molecular diagnostics

Executive Summary

Certus Molecular Diagnostics AG is a Swiss-based private molecular diagnostics company founded in 2017 and headquartered in Zollikofen. The company focuses on developing innovative diagnostic solutions, leveraging molecular biology techniques to address unmet needs in disease detection and monitoring. While specific product details and financial information are limited, Certus operates in the highly competitive diagnostics sector with potential applications in infectious disease, oncology, or genetic testing. The company's stage and total funding are undisclosed, indicating it may be in early development or privately held with limited public disclosure. Given the growing demand for rapid and accurate molecular diagnostics, Certus could be positioning itself to capture market share through novel assays or point-of-care technologies. However, without clear visibility into its pipeline or commercial products, the near-term outlook remains uncertain.

Upcoming Catalysts (preview)

• Q4 2026Partnership or licensing agreement with a larger diagnostics firm40% success
• Q2 2027Publication of clinical validation data for lead diagnostic assay30% success
• Q3 2027CE marking or regulatory clearance in European markets25% success